For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...

In a recent interview following the 2026 ASCO Genitourinary Cancers Symposium, Karie Danielle Keera Runcie, MD, assistant ...

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous ...

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...

Vincent Ma, MD, discusses the next steps in proving the value of circulating tumor DNA in predicting outcomes of advanced ...

Multinational real-world use across 23 centers yielded efficacy broadly aligned with MajesTEC-1, supporting external validity for teclistamab in late-line RRMM. Response depth tracked with durability, ...

Universal month-3 NGF MRD negativity (10⁻⁵) followed short-course VRd or daratumumab-based induction and single-infusion YK-hBCMA BB-002, despite high-risk biology and frailty representation. Depth of ...

New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials. In an interview with Targeted Oncology, Rutika Mehta, MD, MPH ...

Confirmed objective responses were observed at 8.6 and 10 mg/kg q3w, with a high overall disease control rate in late-line metastatic colorectal cancer. Progression-free survival estimates near 7 ...

This biological process, where mature, specialized cells lose their distinct characteristics and revert to a more primitive, aggressive state, is a universally recognized sign of poor prognosis across ...

Dr. Antoni Vilaseca Cabo discusses using an intravesical drug delivery system to continuously administer the FGFR inhibitor ...